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Background: Optimal relief of pain after knee arthroscopy is essential for early rehabilitation and mobilisation and to minimise 
postoperative morbidity. This study’s aim was to assess dexmedetomidine as an additive to intra-articular (IA) bupivacaine in 
terms of analgesic duration and postoperative rescue analgesic consumption following arthroscopic knee surgery.
Methods: A total of 70 patients, ASA physical status I and II, undergoing knee arthroscopy under general anaesthesia were 
enrolled in this double-blinded randomised controlled study, after Pan African Clinical Trial Registry (PACTR201507001048242) 
approval was obtained. Patients were randomly assigned into two groups; the bupivacaine group (B) received IA 19  ml 
bupivacaine 0.5% + 1 ml normal saline, bupivacaine dexmedetomidine group (BD) received IA injection of 19 ml bupivacaine 
0.5% + dexmedetomidine 100 μg (1 ml). Postoperative visual analogue pain score (VAS), duration of analgesia and postoperative 
analgesic requirement were assessed.
Results: VAS scores at rest and on mobilisation were significantly lower in the BD group at 4  h, 6  h and 8  h postoperatively 
in comparison with group B (p < 0.05). VAS scores were comparable between studied groups during the first 2 h, and at 12 h 
and 24 h postoperatively. Duration of analgesia was significantly longer in group BD (458.9 ± 93.5 min) than in the B group 
(229.1 ± 83.7 min) (p < 0.05). Postoperative analgesic consumption was lowered in the BD group compared with the B group 
(p < 0.05).
Conclusions: Adding dexmedetomidine to IA bupivacaine after knee arthroscopy prolongs analgesic duration and decreases 
postoperative analgesic requirement.
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Introduction
Knee arthroscopy is a well-established minimally invasive 
procedure. Arthroscopic surgery is often associated with a 
considerable degree of postoperative pain, usually caused by 
stimulation of the synovial tissue free nerve endings, anterior fat 
pad and capsule of the joint by either surgical excision or 
resection.1
Although arthroscopic knee procedures are less traumatic than 
open surgery, considerable postoperative pain can prevent early 
mobilisation and rehabilitation and reduce patient satisfaction.2 
Many techniques for postoperative analgesia have been studied 
(for example, systemic analgesia, neuraxial analgesia, peripheral 
nerve blocks and intra-articular (IA) injections) in an attempt to 
establish the best modality for control of postoperative pain.3
A single IA injection of local anaesthetic (LA) has been used to 
adequately provide analgesia after arthroscopic knee surgery 
and to reduce consumption and possible side effects of systemic 
analgesics. IA bupivacaine is commonly used due to its prolonged 
analgesic effect4 as well as its established ability to reduce rescue 
analgesic consumption.1
Many studies have used different IA agents such as opioids, 
ketamine, NSAIDS and α2 adrenergic agonists for pain 
management after knee surgeries.5,6 Dexmedetomidine is a 
potent and highly selective α2 adrenoreceptor agonist that binds 
the α2-receptors up to eight times more avidly than clonidine, 
with well-recognised sedative-hypnotic, anxiolytic, analgesic, 
anaesthetic and sympatholytic effects.7 Intravenous and intra-
articular dexmedetomidine have been used in several studies to 
enhance postoperative analgesia after knee arthroscopy and 
have demonstrated an increased time to first analgesic request 
and a decreased need for postoperative analgesia.5,6
IA dexmedetomidine has been used before in doses of 50 μg and 
80 μg. So, we hypothesised that IA dexmedetomidine at 100 μg 
would result in satisfactory prolongation of analgesic duration 
without increased adverse effects.
Our aim was to assess dexmedetomidine as an adjuvant to IA 
bupivacaine on analgesic duration and postoperative analgesic 
consumption after arthroscopic surgical procedures of the knee.
Material and methods
After obtaining approval from the Institutional Review Board, 
Tanta University, Faculty of Medicine, Tanta, Egypt (2971/12/14), 
the Pan African Clinical Trial Registry (PACTR201507001048242) 
and patients’ informed written consent, a prospective double-
blinded randomised controlled study was carried out on 70 adult 
patients aged > 18 years, of either gender, with American Society 
of Anesthesiologists physical status (ASA) I–II undergoing knee 
arthroscopy. The study was carried out between January and 
July 2015.
All patients’ data were kept confidential with secret codes and in 
a private file for each patient. All given data were used for the 
current research only. Any unexpected adverse effects occurring 
during the research were explained to the patients and reported 
to the ethical committee at the time. The study protocol and the 
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VAS for pain assessment were explained to each patient 
preoperatively.
The exclusion criteria comprised patients with prolonged intake 
of NSAIDs, opioids, calcium channel blockers, corticosteroids, 
tricyclic antidepressants, or those with psychiatric disorders, 
patients who received analgesics up to 24 h prior to surgery, liver 
or renal disease, or allergy to studied medications were excluded.
Computer-generated randomisation numbers were used to 
allocate patients into two groups using sealed opaque envelopes 
chosen by each patient. In the bupivacaine group (B), patients 
had an IA injection of 19  ml bupivacaine 0.5%  +  1  ml normal 
saline. In the bupivacaine dexmedetomidine group (BD), patients 
had an IA injection of 19 ml bupivacaine 0.5% + dexmedetomidine 
100 μg (1 ml).
The studied medications were prepared by an anaesthesiologist 
with no subsequent role in the study to ensure blinding.
Premedication with 0.05 mg/kg IV midazolam was given 15 min 
before induction of anaesthesia. Monitoring included five-lead 
ECG, pulse oximetry, non-invasive blood pressure and 
capnography. Induction of general anaesthesia was with IV 
propofol 2 mg/kg, fentanyl 1 μg/kg, and intubation was facilitated 
with cisatracurim 0.15 mg/kg. Anaesthesia was maintained with 
1:1 O2:air mixture, isoflurane 1.2–1.5% and patients were 
mechanically ventilated.
Once the patient was anaesthetised, inflation of the tourniquet 
and sterilisation of the surgical field were performed. 
Subsequently, a standard arthroscopy technique was performed 
by the same surgeon through two portals, one anterolateral and 
one anteromedial. At the end of surgery and 10  min before 
tourniquet deflation, the study drug was injected into the joint 
after stitching the portals to prevent extravasation. This was 
taken as the start time to determine time to first request for 
analgesia. The tourniquet was removed after application of a 
compression bandage.
Inhalational anaesthesia was discontinued, and muscle relaxant 
was reversed by neostigmine sulphate 0.05 mg/ kg and atropine 
sulphate 0.02  mg/ kg. Patients were transferred to the Post 
Anaesthesia Care Unit (PACU) where VAS was assessed on 
admission to PACU, and at 30 min, 1 h, 2 h, 4 h, 6 h, 8 h, 12 h and 
24 h both at rest (VASr) and on mobilisation (VASm) (bending of 
the operated knee). A dose of 1  g IV paracetamol was 
administered to all patients if VAS was ≥ 4 then repeated 6 h later. 
Rescue analgesia of 30  mg IV pethidine was administered if, 
20  min after paracetamol injection, VAS was still  ≥  4. Total 
paracetamol and pethidine consumption was recorded.
Our primary outcome was the duration of analgesia defined as 
the time elapsed from IA injection to time of first analgesic 
request. Secondary outcome was the total 24 h rescue analgesic 
consumption. Adverse events including nausea, vomiting, 
hypotension, bradycardia, depression of respiration and sedation 
were recorded, as well as patients’ satisfaction levels. Local 
adverse effects such as haematoma were recorded. Nausea and 
vomiting were treated with ondansetron 4 mg IV. Hypotension 
(defined as a decrease in mean arterial pressure more than 20% 
of the baseline value) was treated with intravenous fluids and 
intravenous ephedrine 10  mg boluses as needed. Bradycardia 
(defined as heart rate less than 50 beat/min) was treated by 
atropine 0.01  mg/kg IV. Patients were discharged 24 h 
postoperatively.
Statistical analysis
Sample-size calculation was based on the prolongation of time 
of first analgesic request. Based on the results of previous study5 
at least 29 patients in each group were needed to detect a 
significant prolongation of 90 min at α error of 0.05 and study 
power of 80%.
We used the Statistical Package for the Social Sciences (SPSS®) 16 
software (SPSS Inc., Chicago, IL, USA) for statistical analysis. A 
Kolmogorov–Smirnov test was performed for verification of the 
assumption of normality. Quantitative data were described as 
mean  ±  SD and independent sample t-test was used for 
comparison between the two groups. Categorical data were 
described as number or frequencies (%) and chi-square test or 
Fisher’s exact test were used as appropriate for comparison 
between both groups. A p-value  <  0.05 was considered 
significant.
Results
Seventy-eight patients were evaluated for enrolment in the 
study. Seventy patients were randomly allocated into one of two 
groups after exclusion of eight patients (Figure 1).
Demographic data including age, weight, gender and duration 
of surgical procedure were comparable among the two studied 
groups (p > 0.05) (Table 1).
Time to first request for analgesia was significantly longer in the 
BD group (458.9  ±  93.5  min) in comparison with the B group 
(229.1 ± 83.7 min) (p < 0.05) (Table 2).
Total postoperative paracetamol consumption was significantly 
decreased in the BD group (2.57 ± 0.44 g) compared with the B 
group (3.11 ± 0.47 g) (p < 0.05) (see Table 2).
Nine patients requested postoperative rescue analgesia in the 
BD group, which was significantly lower compared with the B 
group (22 patients) (p < 0.05) (see Table 2).
Total postoperative rescue analgesia consumption was 
significantly lower in the BD group (21.40 ± 38.90 mg) compared 
with the B group (61.70 ± 52.90 mg) (p < 0.05) (see Table 2).
VAS scores at rest and on mobilisation were statistically 
comparable among the two studied groups from time of 
admission to PACU up to 2  h postoperatively (p  >  0.05). VAS 
scores were significantly lower in the BD group than the B group 
at 4  h, 6  h and 8  h postoperatively (p  <  0.05). No statistically 
significant difference was detected between the two studied 
groups at 12 h and 24 h (p > 0.05) (Table 3).
No significant complications were detected in either groups. 
Patient satisfaction was significantly higher in the BD group in 
comparison with the B group (Table 4).
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Discussion
Results of this study showed that adding dexmedetomidine 
100 μg to IA bupivacaine results in prolongation of analgesia as 
well as reduction of postoperative analgesic requirements and 
better patient satisfaction than bupivacaine alone.
Single IA injection of LA has been suggested to provide adequate 
pain management after arthroscopy of the knee joint and to 
reduce consumption and possible adverse effects of systemic 
analgesics. IA bupivacaine is frequently used because of its 
extended duration of action.4
The duration of analgesia provided by a single dose of IA 
bupivacaine is not well defined. Møiniche et al.8 stated that the 
lower pain score due to bupivacaine was short in duration, and 
some studies9,10 have demonstrated bupivacaine to be superior 
to placebo for the first 2–4 h only. In contrast, other studies11,12 
showed bupivacaine to have an enhanced and longer analgesic 
effect than placebo in the first 24 h.
In other studies,13,14 bupivacaine dose and concentration were 
augmented with epinephrine to obtain a longer analgesic effect. 
A meta-analysis by Wei et al.4 stated that a single IA dose of 
bupivacaine is superior to placebo in providing pain relief 
Figure 1: CONSORT flow diagram of participants through each stage of the randomised trial
Table 1: Demographic data and duration of surgery in studied groups
Notes: Data are expressed as mean ± SD or patient number.
*p < 0.05 denotes statistical significance.
Item B group BD group p-value
Age (years) 35.17±9.78 34.89±9.22 0.90
Gender (M/F) 32/3 31/4 0.69
Body weight (kg) 80.26±9.09 81.60±8.73 0.53
Duration of surgery (min) 52.1±11.3 54.3±11.5 0.44
Table 2: Analgesic requirements in studied groups
Notes: Data are expressed as mean ± SD and patient number.
*p < 0.05 denotes statistical significance.
CI = confidence interval.
Item B group BD group p-value 95% CI
Paracetamol consumption (g) 3.11 ± 0.47 2.57 ± 0.44 0.000* 0.639–1.075
Number of patients requiring rescue analgesia 22/35 9/35 0.002*
Total consumption of rescue analgesia (mg) 61.70 ± 52.90 21.40 ± 38.90 0.001* 18.1–62.5
Time of first analgesic request (min) 229.1 ± 83.7 458.9 ± 93.5 0.000* 57.2–349.0
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analgesic pathway modulation may be an alternative explanation 
for the analgesic effect of dexmedetomidine.23
Consistent with our study, El-Hamamsy et al. compared 
dexmedetomidine versus fentanyl as additives to IA bupivacaine 
and found similar efficacy when compared with bupivacaine 
alone.24 They reported that IA dexmedetomidine 1 μg/kg when 
added to bupivacaine resulted in significant improvement of 
postoperative analgesia after knee arthroscopy, with longer time 
to first analgesic requirement (450  ±  85  min) compared with 
bupivacaine alone (230  ±  85  min), and decreased meperidine 
requirement during the first 24 h.24
Paul et al. demonstrated that the addition of dexmedetomidine 
to ropivacaine local anaesthetic enhances both the quality as 
well as the duration of postoperative analgesia after knee 
arthroscopy and reduces fentanyl consumption, with an average 
of 10.84  ±  2.6  h between IA injection and supplementary 
analgesic administration by PCA pump.25
In a study by Reuben and Connelly,26 the mean time to first 
analgesic request following knee arthroscopy was 500 min after 
IA clonidine, 325 min after IA bupivacaine and 700 min after 
combined IA clonidine and bupivacaine.
In another study by Joshi and colleagues,27 the mean time to first 
analgesic request after knee arthroscopy was 280 min after IA 
bupivacaine, 600 min after IA clonidine, 720 min after IA 
bupivacaine and morphine and 950 min after combined IA 
clonidine, bupivacaine and morphine. Al-Metwalli et al.5 
concluded that IA dexmedetomidine alone provided around 312 
min mean time of postoperative analgesia after knee arthroscopy. 
No systemic side effects were observed in any of the study 
groups. The lack of systemic effects in the IA injections may be 
following knee arthroscopy. Analgesic properties including 
greater duration of postoperative analgesia, rescue analgesic 
reduction and lower postoperative VAS scores after IA 
bupivacaine administration were also documented in other 
studies.15–18
Dexmedetomidine is an α2 agonist with spinal, supraspinal and 
peripheral actions. The IA analgesia produced by 
dexmedetomidine may be attributed to direct local action. A 
central analgesic effect caused by systemic absorption may also 
be possible.19
The analgesic effect of IA dexmedetomidine might be similar to 
that of IA clonidine. Clonidine inhibits peripheral norepinephrine 
release at afferent nociceptors through its effect on α2 adrenergic 
presynaptic receptors.20 Dexmedetomidine has been shown to 
inhibit the conduction of nerve signals in C and Aδ fibres and 
promotes the release of encephalin-like substances at peripheral 
sites thereby producing local anaesthetic effects.21,22 Opioid-
Table 3: Visual analogue scale (VAS) at rest and on mobilisation in studied groups
Notes: Data presented as mean ± SD.
*p < 0.05 denotes statistical significance.
CI = confidence interval.
Item B BD p-value 95% CI
VAS at rest On admission 1.62 ± 0.59 1.42 ± 0.60 0.170 (–0.088; 0.488)
30 min 1.54 ± 0.61 1.48 ± 0.70 0.717 (–0.257; 0.371)
1 h 1.51 ± 0.61 1.45 ± 0.56 0.685 (–0.223; 0.337)
2 h 1.45 ± 0.65 1.34 ± 0.48 0.410 (–0.161; 0.390)
4 h 3.00 ± 0.80 1.77 ± 0.87 0.000 * (0.827; 1.630)
6 h 3.20 ± 0.58 1.71 ± 0.86 0.000 * (1.134; 1.837)
8 h 4.02 ± 0.70 2.37 ± 0.77 0.000 * (1.305; 2.010)
12 h 2.17 ± 0.74 1.88 ± 0.86 0.144 (–0.100; 0.672)
24 h 1.54 ± 0.61 1.45 ± 0.61 0.559 (–0.206; 0.377)
VAS on mobilisation On admission 2.09 ± 0.74 1.97 ± 0.92 0.570 (–0.286; 0.514)
30 min 2.17 ± 0.71 1.94 ± 0.84 0.222 (–0.141; 0.599)
1 h 2.11 ± 0.63 2.00 ± 0.73 0.485 (–0.211; 0.439)
2 h 2.20 ± 0.53 2.03 ± 0.62 0.218 (–0.104; 0.446)
4 h 4.31 ± 0.83 2.31 ± 0.79 0.000 * (1.611; 2.389)
6 h 4.20 ± 0.79 2.29 ± 1.07 0.000 * (1.463; 2.366)
8 h 4.91 ± 0.91 2.80 ± 1.18 0.000 * (1.608; 2.620)
12 h 2.60 ± 0.73 2.31 ± 1.08 0.200 (–0.156; 0.727)
24 h 1.88 ± 0.67 1.91 ± 0.78 0.871 (–0.377; 0.320)
Table 4: Adverse events and patient satisfaction
Notes: Data are presented as number (%).
 *p < 0.05 denotes statistical significance.
Item B group BD group p-value
Complications Hypotension 0 (00%) 2 (5.7%) 0.493
Bradycardia 0 (00%) 3 (8.5%) 0.239
Satisfaction Satisfied 17 (48%) 29 (82%) 0.007*
Fair 11 (31%) 5 (14%)
Dissatisfied 7 (20%) 1 (2%)
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solutions. Bogatch et al.30 did not find toxicity due to adrenaline 
or low pH. They suggested an alternative hypothesis of an 
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In addition, Akça et al.31 reported no adverse effects of 
dexmedetomidine on rat knee cartilage but little is known about 
any effects in humans.
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bupivacaine prolongs duration of analgesia, decreases 
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